US 12,084,494 B2
Interleukin-31 monoclonal antibodies for veterinary use
Gary Francis Bammert, Portage, MI (US); Steven Alan Dunham, Kalamazoo, MI (US); and Sebastian C. J. Steiniger, Kalamazoo, MI (US)
Assigned to Zoetis Services LLC, Parsippany, NJ (US)
Filed by Zoetis Services LLC, Parsippany, NJ (US)
Filed on Jan. 7, 2022, as Appl. No. 17/571,117.
Application 17/571,117 is a continuation of application No. 16/256,223, filed on Jan. 24, 2019, granted, now 11,530,262.
Claims priority of provisional application 62/643,940, filed on Mar. 16, 2018.
Prior Publication US 2022/0127351 A1, Apr. 28, 2022
Int. Cl. A61K 39/00 (2006.01); A61P 17/00 (2006.01); A61P 35/00 (2006.01); A61P 37/00 (2006.01); C07K 16/24 (2006.01); G01N 33/68 (2006.01)
CPC C07K 16/244 (2013.01) [A61P 17/00 (2018.01); A61P 35/00 (2018.01); A61P 37/00 (2018.01); G01N 33/6869 (2013.01); A61K 2039/505 (2013.01); A61K 2039/552 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 2333/54 (2013.01)] 6 Claims
 
1. An anti-IL31 antibody, which is a variant of a parent antibody, the parent antibody comprising:
a VH-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 19, a VH-CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 20, a VH-CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 21, a VL-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 22, a VL-CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 23, and a VL-CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 24, wherein the variant antibody is selected from a) a variant wherein the Alanine (A) at position 14 of SEQ ID NO: 20 of the parent antibody is substituted with a Serine (S); or b) a variant wherein the Serine (S) at position 5 of SEQ ID NO: 19 of the parent antibody is substituted with an Asparagine (N) and the Alanine (A) at position 14 of SEQ ID NO: 20 of the parent antibody is substituted with a Serine (S).